ICYMI: B-cell depletion therapy with obinutuzumab, a type II anti-CD20 monoclonal antibody, in lupus nephritis patients was shown to be effective in in combination with standard lupus therapies. https://t.co/pMXWmuJw5Y https://t.co/RhWdVir6yB